Use of selective serotonin reuptake inhibitors and risk of fracture: A systematic review and meta-analysis

Journal of Bone and Mineral Research

Volumn 27, Issue 5, 2012, Pages 1186-1195

  Eom, Chun Sick ^a   Lee, Hyun Ki ^b   Ye, Sungmin ^b   Park, Sang Min ^b   Cho, Kyung Hwan ^c  

^a Korea University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Korea University Ansan Hospital   (South Korea)

Author keywords

ANTIDEPRESSANTS; FRACTURE; META ANALYSIS; SELECTIVE SEROTONIN REUPTAKE INHIBITOR

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

BONE DENSITOMETRY; BONE DENSITY; DRUG USE; FRACTURE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

DATABASES AS TOPIC; DEPRESSION; FRACTURES, BONE; HUMANS; MEDLINE; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 84859906973     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1554     Document Type: Review

References (53)

1. Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011; 9: 257-67.
2. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011; 183: 310-9.
3. Schwan S, Hallberg P., SSRIs, bone mineral density, and risk of fractures-a review. Eur Neuropsychopharmacol. 2009; 19: 683-92.
4. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med. 2007; 167: 1240-5.
5. Poole KE, Compston JE., Osteoporosis and its management. BMJ. 2006; 333: 1251-6.
6. Cummings SR, Melton LJ., Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002; 359: 1761-7.
7. Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General [Internet]. Rockville, MD: US Department of Health and Human Services; 2004 Oct 14 [accessed 2011 Oct]. Available from:.
8. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007; 22: 465-75.
9. Ostbye T, Kristjansson B, Hill G, et al. Prevalence and predictors of depression in elderly Canadians: the Canadian Study of Health and Aging. Chronic Dis Can. 2005; 26: 93-9.
10. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life. Consensus statement update. JAMA. 1997; 278: 1186-90.
11. Spigset O, Martensson B., Fortnightly review: drug treatment of depression. BMJ. 1999; 318: 1188-91.
12. Lewis CE, Ewing SK, Taylor BC, et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res. 2007; 22: 211-9.
13. Verdel BM, Souverein PC, Egberts TC, et al. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010; 47: 604-9.
14. van den Brand MW, Pouwels S, Samson MM, et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int. 2009; 20: 1705-13.
15. Abrahamsen B, Brixen K., Mapping the prescriptiome to fractures in men-a national analysis of prescription history and fracture risk. Osteoporos Int. 2009; 20: 585-97.
16. Bolton JM, Metge C, Lix L, et al. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol. 2008; 28: 384-91.
17. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008; 28: 411-7.
18. Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med. 2008; 23: 567-74.
19. Donaldson LJ, Reckless IP, Scholes S, et al. The epidemiology of fractures in England. J Epidemiol Community Health. 2008; 62: 174-80.
20. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007; 167: 188-94.
21. Vestergaard P, Rejnmark L, Mosekilde L., Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006; 17: 807-16.
22. Hubbard R, Farrington P, Smith C, et al. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003; 158: 77-84.
23. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998; 351: 1303-7.
24. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998; 339: 875-82.
25. Arfken CL, Wilson JG, Aronson SM., Retrospective review of selective serotonin reuptake inhibitors and falling in older nursing home residents. Int Psychogeriatr. 2001; 13: 85-91.
26. Warden SJ, Bliziotes MM, Wiren KM, et al. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol. 2005; 242: 1-9.
27. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa, ON: Ottawa Hospital Research Institute; [accessed 2011 Oct]. Available from:.
28. Kanis JA, Borgstrom F, Laet CD, et al. Assessment of fracture risk. Osteoporos Int. 2005; 16: 581-9.
29. WHO Fracture Risk Assessment Tool (FRAX) [Internet]. Sheffield, UK: WHO Collaborating Center for Metabolic Bone Diseases; [accessed 2011 Nov]. Available from:.
30. Wu Q, Liu J, Gallegos-Orozco JF, et al. Depression, fracture risk, and bone loss: a meta-analysis of cohort studies. Osteoporos Int. 2010; 21: 1627-35.
31. Mussolino ME., Depression and hip fracture risk: The NHANES I epidemiologic follow-up study. Public Health Rep. 2005; 120: 71-5.
32. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-60.
33. DerSimonian R, Laird N., Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-88.
34. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003; 163: 949-57.
35. Pacher P, Ungvari Z., Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses. 2001; 57: 469-71.
36. Ginzburg R, Rosero E., Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann Pharmacother. 2009; 43: 98-103.
37. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit. 2001; 23: 435-40.
38. Bliziotes M, Gunness M, Eshleman A, et al. The role of dopamine and serotonin in regulating bone mass and strength: studies on dopamine and serotonin transporter null mice. J Musculoskelet Neuronal Interact. 2002; 2: 291-5.
39. Westbroek I, van der Plas A, de Rooij KE, et al. Expression of serotonin receptors in bone. J Biol Chem. 2001; 276: 28961-8.
40. Bliziotes MM, Eshleman AJ, Zhang XW, et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone. 2001; 29: 477-86.
41. Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res. 2004; 19: 1420-31.
42. Bliziotes M, Eshleman A, Burt-Pichat B, et al. Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone. 2006; 39: 1313-21.
43. Tsapakis EM, Gamie Z, Tran GT, et al. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry. 2011 Feb 2. [Epub ahead of print].
44. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135: 825-37.
45. Gustafsson BI, Thommesen L, Stunes AK, et al. Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem. 2006; 98: 139-51.
46. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007; 167: 1246-51.
47. Cauley JA, Fullman RL, Stone KL, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int. 2005; 16: 1525-37.
48. Williams LJ, Henry MJ, Berk M, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol. 2008; 23: 84-7.
49. Sambrook P, Cooper C., Osteoporosis. Lancet. 2006; 367: 2010-8.
50. Moride Y, Abenhaim L., Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994; 47: 731-7.
51. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Eng J Med. 1996; 355: 1176-81.
52. Gullberg B, Johnell O, Kanis JA., World-wide projections for hip fracture. Osteoporos Int. 1997; 7: 407-13.
53. Kanis JA., The incidence of hip fracture in Europe. Osteoporos Int. 1993; 3: 10-5.